A Phase 2a Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractor
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Molecular Templates, Inc.
Start Date
January 23, 2019
End Date
July 31, 2023
Administered By
Duke Cancer Institute
Awarded By
Molecular Templates, Inc.
Start Date
January 23, 2019
End Date
July 31, 2023